CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.

The T cell compartment of adaptive immunity provides vertebrates with the potential to survey for and respond specifically to an incredible diversity of antigens. The T cell repertoire must be carefully regulated to prevent unwanted responses to self. In the periphery, one important level of regulation is the action of costimulatory signals in concert with T cell antigen-receptor (TCR) signals to promote full T cell activation. The past few years have revealed that costimulation is quite complex, involving an integration of activating signals and inhibitory signals from CD28 and CTLA-4 molecules, respectively, with TCR signals to determine the outcome of a T cell's encounter with antigen. Newly emerging data suggest that inhibitory signals mediated by CTLA-4 not only can determine whether T cells become activated, but also can play a role in regulating the clonal representation in a polyclonal response. This review primarily focuses on the cellular and molecular mechanisms of regulation by CTLA-4 and its manipulation as a strategy for tumor immunotherapy.

[1]  J. Bluestone,et al.  CTLA-4 ligation blocks CD28-dependent T cell activation [published erratum appears in J Exp Med 1996 Jul 1;184(1):301] , 1996, The Journal of experimental medicine.

[2]  T. Mak,et al.  Duration of TCR stimulation determines costimulatory requirement of T cells. , 1996, Immunity.

[3]  J. Bluestone,et al.  CD28/B7 system of T cell costimulation. , 1996, Annual review of immunology.

[4]  T. Mak,et al.  Regulation of T Cell Receptor Signaling by Tyrosine Phosphatase SYP Association with CTLA-4 , 1996, Science.

[5]  T. Strom,et al.  Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. , 1997, Immunity.

[6]  R. Karr,et al.  Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. , 1995, Journal of immunology.

[7]  J. Bluestone,et al.  CTLA-4 downregulates epitope spreading and mediates remission in relapsing experimental autoimmune encephalomyelitis , 2000, Journal of Neuroimmunology.

[8]  T. Mak,et al.  Normal responsiveness of CTLA-4-deficient anti-viral cytotoxic T cells. , 1998, Journal of immunology.

[9]  T. Sullivan,et al.  Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. , 1996, International immunology.

[10]  K. McCoy,et al.  Protective Immunity to Nematode Infection Is Induced by CTLA-4 Blockade , 1997, The Journal of experimental medicine.

[11]  D. Farber,et al.  Differential role of CTLA-4 in regulation of resting memory versus naive CD4 T cell activation. , 1998, Journal of immunology.

[12]  E. Jaffee,et al.  Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. , 1994, Science.

[13]  K. Bennett,et al.  Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. , 1996, Immunity.

[14]  S. Almo,et al.  Structure of murine CTLA-4 and its role in modulating T cell responsiveness. , 2000, Science.

[15]  C. Thompson,et al.  Induction of T Cell Anergy in the Absence of CTLA-4/B7 Interaction1 , 2000, The Journal of Immunology.

[16]  A. Lanzavecchia,et al.  T lymphocyte costimulation mediated by reorganization of membrane microdomains. , 1999, Science.

[17]  J. Allison,et al.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation , 1995, The Journal of experimental medicine.

[18]  J. Allison,et al.  CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones , 1992, Nature.

[19]  J. Allison,et al.  The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression. , 1990, Journal of immunology.

[20]  J. Allison,et al.  CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells , 1996, The Journal of experimental medicine.

[21]  K. McCoy,et al.  Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Can Regulate Dendritic Cell–induced Activation and Cytotoxicity of CD8+ T Cells Independently of CD4+T Cell Help , 1999, The Journal of experimental medicine.

[22]  A. Weiss,et al.  CD28 mediates transcriptional upregulation of the interleukin-2 (IL-2) promoter through a composite element containing the CD28RE and NF-IL-2B AP-1 sites , 1997, Molecular and cellular biology.

[23]  P. Linsley,et al.  Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. , 1994, Immunity.

[24]  J. Allison,et al.  The role of tyrosine phosphorylation and PTP‐1C in CTLA‐4 signal transduction , 1996, European journal of immunology.

[25]  J. Allison,et al.  CTLA-4-Mediated inhibition of early events of T cell proliferation. , 1999, Journal of immunology.

[26]  D. Wraith,et al.  Phenotypic analysis of CTLA-4 and CD28 expression during transient peptide-induced T cell activation in vivo. , 1999, International immunology.

[27]  J. Bluestone,et al.  T cell co-stimulation and in vivo tolerance. , 1993, Current opinion in immunology.

[28]  D. Harlan,et al.  CTLA4 (CD152) modulates the Th subset response and alters the course of experimental Leishmania major infection , 1998, European journal of immunology.

[29]  J. Allison,et al.  The lymphoproliferative defect in CTLA-4-deficient mice is ameliorated by an inhibitory NK cell receptor. , 2002, Blood.

[30]  J. Lamb,et al.  Intranasal exposure to protein antigen induces immunological tolerance mediated by functionally disabled CD4+ T cells. , 1999, Journal of immunology.

[31]  J. Madrenas,et al.  The Inhibitory Function of CTLA-4 Does Not Require Its Tyrosine Phosphorylation1 , 2000, The Journal of Immunology.

[32]  C. Benoist,et al.  Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Regulates the Unfolding of Autoimmune Diabetes , 1998, The Journal of experimental medicine.

[33]  A. Weiss,et al.  ZAP-70 is constitutively associated with tyrosine-phosphorylated TCR zeta in murine thymocytes and lymph node T cells. , 1994, Immunity.

[34]  D I Stuart,et al.  Structure and dimerization of a soluble form of B7-1. , 2000, Immunity.

[35]  J. Bluestone,et al.  Regulation of cytotoxic T lymphocyte-associated molecule-4 by Src kinases. , 1999, Journal of immunology.

[36]  H. Nariuchi,et al.  Polarization of Naive CD4+ T Cells Toward the Th1 Subset by CTLA-4 Costimulation1 , 2000, The Journal of Immunology.

[37]  P. Nickerson,et al.  CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. , 1997, Journal of immunology.

[38]  J. Allison,et al.  The Role of CTLA‐4 in the Regulation and Initiation of T‐Cell Responses , 1996, Immunological reviews.

[39]  M. Jenkins,et al.  CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. , 1991, Journal of immunology.

[40]  T. Mak,et al.  Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4 , 2000, The Journal of experimental medicine.

[41]  A. Kruisbeek,et al.  Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) Interferes with Extracellular Signal-regulated Kinase (ERK) and Jun NH2-terminal Kinase (JNK) Activation, but Does Not Affect Phosphorylation of T Cell Receptor ζ and ZAP70 , 1997, The Journal of experimental medicine.

[42]  P. Blair,et al.  Cutting Edge: CTLA-4 Ligation Delivers a Unique Signal to Resting Human CD4 T Cells That Inhibits Interleukin-2 Secretion but Allows Bcl-XL Induction , 1998, The Journal of Immunology.

[43]  D. Baltimore,et al.  Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. , 1999, Immunity.

[44]  P. Linsley,et al.  CTLA-4 can function as a negative regulator of T cell activation. , 1994, Immunity.

[45]  J. Bluestone,et al.  B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. , 2000, Immunity.

[46]  Peter S. Linsley,et al.  Cytotoxic T Lymphocyte-associated Molecule-4, a High Avidity Receptor for CD80 and CD86, Contains an Intracellular Localization Motif in Its Cytoplasmic Tail (*) , 1995, The Journal of Biological Chemistry.

[47]  J. Allison,et al.  Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation , 1999, The Journal of experimental medicine.

[48]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[49]  T. Sullivan,et al.  Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. , 1997, Immunity.

[50]  J. Allison,et al.  Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[51]  J. Bluestone,et al.  Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses. , 1999, Journal of immunology.

[52]  P. Linsley,et al.  Covalent Dimerization of CD28/CTLA-4 and Oligomerization of CD80/CD86 Regulate T Cell Costimulatory Interactions* , 1996, The Journal of Biological Chemistry.

[53]  H. Schneider,et al.  CD28 receptor endocytosis is targeted by mutations that disrupt phosphatidylinositol 3-kinase binding and costimulation. , 1998, Journal of immunology.

[54]  C. Benoist,et al.  Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[55]  F. Denizot,et al.  A new member of the immunoglobulin superfamily—CTLA-4 , 1987, Nature.

[56]  G. Freeman,et al.  Characterization of CTLA-4 structure and expression on human T cells. , 1993, Journal of immunology.

[57]  J. Bluestone,et al.  CTLA-4 regulates tolerance induction and T cell differentiation in vivo. , 1998, Journal of immunology.

[58]  Nitin J. Karandikar,et al.  CTLA-4: a negative regulator of autoimmune disease , 1996, The Journal of experimental medicine.

[59]  K. Bennett,et al.  Interaction of the cytoplasmic tail of CTLA-4 (CD152) with a clathrin-associated protein is negatively regulated by tyrosine phosphorylation. , 1997, Biochemistry.

[60]  C. Langlet,et al.  Membrane rafts and signaling by the multichain immune recognition receptors. , 2000, Current opinion in immunology.

[61]  A. Khoruts,et al.  CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. , 1999, Immunity.

[62]  B. Foster,et al.  Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[63]  J. Hutchcroft,et al.  Signaling through CD28/CTLA-4 family receptors: puzzling participation of phosphatidylinositol-3 kinase. , 1996, Journal of immunology.

[64]  Masahiko Hibi,et al.  JNK is involved in signal integration during costimulation of T lymphocytes , 1994, Cell.

[65]  R. Germain,et al.  CD4+ T cell survival is not directly linked to self-MHC–induced TCR signaling , 2000, Nature Immunology.

[66]  C. Benoist,et al.  Mice Lacking H2-M Complexes, Enigmatic Elements of the MHC Class II Peptide-Loading Pathway , 1996, Cell.

[67]  M. Azuma,et al.  Augmentation of CTLA-4 expression by wortmannin: involvement of lysosomal sorting properties of CTLA-4. , 1999, International immunology.

[68]  M. V. Vander Heiden,et al.  Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression. , 1997, Journal of immunology.

[69]  K. Tanaka,et al.  Janus kinase 2 is associated with a box 1‐like motif and phosphorylates a critical tyrosine residue in the cytoplasmic region of cytotoxic T lymphocyte associated molecule‐4 , 2000, Journal of cellular biochemistry.

[70]  J. Bonifacino,et al.  Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2. , 1997, Immunity.

[71]  C. Thompson,et al.  Structural Analysis of CTLA-4 Function In Vivo1 , 2000, The Journal of Immunology.

[72]  S. Nagata,et al.  The Fas death factor , 1995, Science.

[73]  É. Vivier,et al.  Immunoreceptor Tyrosine-based Inhibition Motifs , 2012, Current Topics in Microbiology and Immunology.

[74]  R. Schwartz,et al.  Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. , 1989, Annual review of immunology.

[75]  J. Allison,et al.  Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis , 1997, Journal of Neuroimmunology.

[76]  H. Schneider,et al.  Tyrosine phosphatase SHP-2 binding to CTLA-4: absence of direct YVKM/YFIP motif recognition. , 2000, Biochemical and biophysical research communications.

[77]  L. Berg,et al.  Cutting Edge: Two Distinct Mechanisms Lead to Impaired T Cell Homeostasis in Janus Kinase 3- and CTLA-4-Deficient Mice1 , 2001, The Journal of Immunology.

[78]  Yuan Zhang,et al.  Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[79]  C. Thompson,et al.  Expression and function of CTLA-4 in Th1 and Th2 cells. , 1998, Journal of immunology.

[80]  R. Flavell,et al.  Abrogation of TGFβ Signaling in T Cells Leads to Spontaneous T Cell Differentiation and Autoimmune Disease , 2000 .

[81]  A. Weiss,et al.  Regulation of T-cell lymphokine gene transcription by the accessory molecule CD28 , 1992, Molecular and cellular biology.

[82]  J. Bluestone,et al.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.

[83]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[84]  M. Jenkins The ups and downs of T cell costimulation. , 1994, Immunity.

[85]  A. Sharpe,et al.  B7-1 or B7-2 Is Required to Produce the Lymphoproliferative Phenotype in Mice Lacking Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) , 1999, The Journal of experimental medicine.

[86]  Seong-Jin Kim,et al.  Disruption of T Cell Homeostasis in Mice Expressing a T Cell–Specific Dominant Negative Transforming Growth Factor β II Receptor , 2000, The Journal of experimental medicine.

[87]  M. Davis,et al.  A receptor/cytoskeletal movement triggered by costimulation during T cell activation. , 1998, Science.

[88]  E. Shevach Regulatory T cells in autoimmmunity*. , 2000, Annual review of immunology.

[89]  B. Foster,et al.  Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. , 2000, Cancer research.

[90]  E. Simpson,et al.  B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. , 1997, Immunity.

[91]  T. Kirchhausen,et al.  Cytolytic T lymphocyte-associated antigen-4 and the TCR zeta/CD3 complex, but not CD28, interact with clathrin adaptor complexes AP-1 and AP-2. , 1999, Journal of immunology.

[92]  T. Mak,et al.  Normal thymic selection, normal viability and decreased lymphoproliferation in T cell receptor‐transgenic CTLA‐4‐deficient mice , 1997, European journal of immunology.

[93]  C. Monks,et al.  Selective modulation of protein kinase C-Θ during T-cell activation , 1997, Nature.

[94]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[95]  J. Madrenas,et al.  CTLA-4 (CD152) Can Inhibit T Cell Activation by Two Different Mechanisms Depending on Its Level of Cell Surface Expression1 , 2000, The Journal of Immunology.

[96]  S. Constant,et al.  Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. , 1997, Annual review of immunology.

[97]  J. Bluestone,et al.  Molecular basis of T cell inactivation by CTLA-4. , 1998, Science.

[98]  C. June,et al.  CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. , 1996, Journal of immunology.

[99]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[100]  P. Linsley,et al.  CTLA-4 is a second receptor for the B cell activation antigen B7 , 1991, The Journal of experimental medicine.

[101]  C. Thompson,et al.  Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. , 1989, Science.

[102]  P. Linsley,et al.  Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. , 1993, Science.

[103]  C. June,et al.  A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes. , 1986, Journal of immunology.

[104]  J. Allison,et al.  CTLA-4--the costimulatory molecule that doesn't: regulation of T-cell responses by inhibition. , 1999, Cold Spring Harbor symposia on quantitative biology.

[105]  K P Lee,et al.  Differential T cell costimulatory requirements in CD28-deficient mice. , 1993, Science.

[106]  J. Allison,et al.  Activation and differentiation requirements of primary T cells in vitro. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[107]  R. Abe,et al.  Cytotoxic T Lymphocyte Antigen 4 (Ctla-4) Engagement Delivers an Inhibitory Signal through the Membrane-Proximal Region in the Absence of the Tyrosine Motif in the Cytoplasmic Tail , 1999, The Journal of experimental medicine.

[108]  T. Honjo,et al.  Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. , 1999, Immunity.

[109]  J. Allison,et al.  In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[110]  A. Sharpe,et al.  The role of CTLA-4 in regulating Th2 differentiation. , 1999, Journal of immunology.

[111]  S. Wahl,et al.  Engagement of Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Induces Transforming Growth Factor β (TGF-β) Production by Murine CD4+ T Cells , 1998, The Journal of experimental medicine.

[112]  Ethan M. Shevach,et al.  CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production , 1998, The Journal of experimental medicine.

[113]  J. Allison,et al.  The emerging role of CTLA-4 as an immune attenuator. , 1997, Immunity.

[114]  J. Allison,et al.  Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[115]  P. Linsley,et al.  Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation , 1991, The Journal of experimental medicine.

[116]  J. Allison,et al.  Cytotoxic T lymphocyte antigen 4 (CD152) regulates self-reactive T cells in BALB/c but not in the autoimmune NOD mouse. , 2000, Journal of autoimmunity.

[117]  G. Legname,et al.  Long-term survival but impaired homeostatic proliferation of Naïve T cells in the absence of p56lck. , 2000, Science.

[118]  J. Bluestone,et al.  Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. , 1998, Cancer research.

[119]  J. Allison,et al.  Manipulation of costimulatory signals to enhance antitumor T-cell responses. , 1995, Current opinion in immunology.

[120]  J. Gribben,et al.  CTLA4 mediates antigen-specific apoptosis of human T cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[121]  T. Mak,et al.  Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. , 1999, Journal of immunology.

[122]  J. Allison,et al.  CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[123]  M. Wilson,et al.  TGF-β Mediates CTLA-4 Suppression of Cellular Immunity in Murine Kalaazar1 , 2000, The Journal of Immunology.

[124]  S. Bromley,et al.  The immunological synapse: a molecular machine controlling T cell activation. , 1999, Science.

[125]  R. Offringa,et al.  Adoptive T Cell Immunotherapy of Human Uveal Melanoma Targeting gp1001 , 2000, The Journal of Immunology.

[126]  J. Allison,et al.  Secondary but not primary T cell responses are enhanced in CTLA‐4‐deficient CD8+ T cells , 1998, European journal of immunology.

[127]  S. Singer,et al.  The specific direct interaction of helper T cells and antigen- presenting B cells. II. Reorientation of the microtubule organizing center and reorganization of the membrane-associated cytoskeleton inside the bound helper T cells , 1987, The Journal of experimental medicine.

[128]  J. Allison,et al.  Thymocyte development is normal in CTLA-4-deficient mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[129]  H. Reiser,et al.  Fas-independent death of activated CD4(+) T lymphocytes induced by CTLA-4 crosslinking. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[130]  J. Bluestone,et al.  Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. , 1997, Cancer research.

[131]  H. Ruley,et al.  H2-M Mutant Mice Are Defective in the Peptide Loading of Class II Molecules, Antigen Presentation, and T Cell Repertoire Selection , 1996, Cell.

[132]  Fiona Powrie,et al.  Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation , 2000, The Journal of experimental medicine.

[133]  M. V. Heiden,et al.  The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A. , 2000, Immunity.

[134]  M. Bevan,et al.  Selecting and maintaining a diverse T-cell repertoire , 1999, Nature.

[135]  P. Bousso,et al.  Defective CTLA-4 cycling pathway in Chediak-Higashi syndrome: a possible mechanism for deregulation of T lymphocyte activation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.